Compare Burlington Stores Inc (BURL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Burlington Stores Inc vs Incyte Corporation — how do they compare? Burlington Stores Inc trades at $354.86 (market cap $22.59B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Burlington Stores Inc and Incyte Corporation are close in size by market cap. Which is the better fit depends on your goals.
| BURL | INCY | |
|---|---|---|
Market Cap | $22.59B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $129.93 |
52-Week Low | $242.43 | $81.61 |
Enterprise Value | $27.71B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $351.88, down 5.28% today but maintains strong technical support near $352. The company demonstrates robust fundamentals with revenue growth from $10.63B to $11.9B projected for 2026, net income margin expansion to 5.23%, and consistent earnings beats. Recent news highlights successful smaller-store strategy execution and multiple analyst upgrades. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $352 and resistance at $365.
BURL presents a compelling growth story with 94% analyst buy ratings and a $367 consensus target offering 4.3% upside. The retailer's margin expansion and store productivity improvements drive optimism, though competitive pressures and consumer spending sensitivity pose risks. Institutional ownership trends show mixed activity with recent insider selling offset by fund position increases.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
